<table>
<thead>
<tr>
<th>APPLICATION NO.</th>
<th>FILING DATE</th>
<th>FIRST NAMED INVENTOR</th>
<th>ATTORNEY DOCKET NO.</th>
<th>CONFIRMATION NO.</th>
</tr>
</thead>
<tbody>
<tr>
<td>09/922,631</td>
<td>08/06/2001</td>
<td>Richard Apodaca</td>
<td>ORT-1473</td>
<td>3570</td>
</tr>
<tr>
<td>00/27777</td>
<td>10/11/2006</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PHILIP S. JOHNSON  
JOHNSON & JOHNSON  
ONE JOHNSON & JOHNSON PLAZA  
NEW BRUNSWICK, NJ 08933-7003

Please find below and/or attached an Office communication concerning this application or proceeding.
The MAILING DATE of this communication appears on the cover sheet with the correspondence address.

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to communication filed on June 19, 2006.

2. The allowed claim(s) is/are 91-101, 103 and 111-114 now renumbered as 1-16.

3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
   a) [ ] All  b) [ ] Some* c) [ ] None of the:
   1. [ ] Certified copies of the priority documents have been received.
   2. [ ] Certified copies of the priority documents have been received in Application No. _____.
   3. [ ] Copies of the certified copies of the priority documents have been received in this national stage application from the international Bureau (PCT Rule 17.2(a)).

   * Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. [ ] A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.

5. [ ] CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
   (a) [ ] including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
      1) [ ] hereto or 2) [ ] to Paper No./Mail Date ______.
   (b) [ ] including changes required by the attached Examiner's Amendment / Comment or in the Office action of
      Paper No./Mail Date ______.

   Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. [ ] DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. [ ] Notice of References Cited (PTO-892)
2. [ ] Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. [ ] Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No./Mail Date 6/19/06
4. [ ] Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. [ ] Notice of Informal Patent Application (PTO-152)
6. [ ] Interview Summary (PTO-413), Paper No./Mail Date ______.
7. [ ] Examiner's Amendment/Comment
8. [ ] Examiner's Statement of Reasons for Allowance
9. [ ] Other ______.
1. **REQUEST FOR CONTINUED EXAMINATION**

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on **19 June 2006** has been entered.

**Information Disclosure Statement**

Applicant's Information Disclosure Statements, filed on **19 June 2006** has been considered. Please refer to Applicant's copy of the 1449 submitted herewith.

**EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with John W. Harbour on 22 August 2006.

The application has been amended as follows:

**Delete** claims 102 and 115.
Delete the phrase “according to claim 103” from the first line of each one of claims 111, 112 and 114.

Delete the phrase “or 99” from each of claims 100, 103, 111, 112, 113 and 114.

Reasons for Allowance

The following is an examiner’s statement of reasons for allowance:

The invention relates to compounds of Formula I, as defined in claim 91 and the pharmaceutical of said compounds. The closest prior art is to Scribner et al, J. Org. Chem. 1997, 62, 1043-1057. Scribner et al teach compounds of Formula

The compounds of this application differ from the compounds of Scribner et al in that \( R^a \) and \( R^b \) (of the compounds of the Formula depicted in claim 91 of this application) together with the nitrogen to which they are attached form a six membered heterocyclic group. The prior art fails to teach or suggest the compounds as described in this application.

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kamal A Saeed whose telephone number is (571) 272-0705. The examiner can normally be reached on M-T 7:00 AM- 5:30 PM.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Mr. Joseph K. McKane, can be reached at (571) 272-0699.

Communication via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by applicant and should be addressed to [joseph.mckane@uspto.gov]. All Internet e-mail communications will be made of record in the application file. PTO employees will not communicate with applicant via Internet e-mail where sensitive data will be exchanged or where there exists a possibility that sensitive data could be identified unless there is of record an express waiver of the confidentiality requirements under 35 U.S.C. 122 by the applicant. See the Interim Internet Usage Policy published by the Patent and Trademark Office Official Gazette on February 25, 1997 at 1195 OG 89.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR only. For more information about the pair system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197.

KAMAL A. SAEED, PH.D.
PRIMARY EXAMINER